Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04831996 · ClinicalTrials.gov registry record · Phase 1
To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Renal Function and Renal Impairment.
A Phase 1 study, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT04831996 is a Phase 1 study that has completed, run by Incyte Corporation. The registered enrollment target is 48 participants.
The verdict
NCT04831996, a Phase 1 study, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the pharmacokinetics and safety of parsaclisib in participants With normal renal function and participants with renal impairment.
Interventions
- DRUG parsaclisib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2021-05-04 |
| Est. Completion | 2022-07-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04831996
The ClinicalTrials.gov registry entry for NCT04831996 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which parsaclisib is the first listed.
NCT04831996 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04831996 about?
NCT04831996 is a clinical study titled "To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Renal Function and Renal Impairment.". The purpose of the study is to evaluate the pharmacokinetics and safety of parsaclisib in participants With normal renal function and participants with renal impairment.
What is the current status of trial NCT04831996?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2021-05-04. Estimated completion is 2022-07-08.
What interventions are being tested in trial NCT04831996?
The interventions under investigation include: parsaclisib (DRUG).
Who is sponsoring clinical trial NCT04831996?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.